Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: A randomized controlled trial

BMC Public Health

Volumn 11, Issue , 2011, Pages

  Dicko, Alassane ^a   Odusanya, Olumuyiwa O ^b   Diallo, Abdoulbaki I ^a   Santara, Gaoussou ^a   Barry, Amadou ^a   Dolo, Amagana ^a   Diallo, Aminata ^c   Kuyinu, Yetunde A ^b   Kehinde, Omolara A ^b   François, Nancy ^d   Borys, Dorota ^d   Yarzabal, Juan P ^d   Moreira, Marta ^d   Schuerman, Lode ^d  

^a UNIVERSITY OF BAMAKO   (Mali)

^b LAGOS STATE UNIVERSITY   (Nigeria)

^c Centre Hospitalo   (Mali)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

10 VALENT PNEUMOCOCCAL VACCINE; 10-VALENT PNEUMOCOCCAL VACCINE; BACTERIAL PROTEIN; CARRIER PROTEIN; GLPQ PROTEIN, HAEMOPHILUS INFLUENZAE; IMMUNOGLOBULIN D; LIPOPROTEIN; PNEUMOCOCCUS VACCINE;

AFRICA SOUTH OF THE SAHARA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNOLOGY; INFANT; MALE; MALI; NIGERIA; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL;

AFRICA SOUTH OF THE SAHARA; BACTERIAL PROTEINS; CARRIER PROTEINS; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; IMMUNOGLOBULIN D; INFANT; LIPOPROTEINS; MALE; MALI; NIGERIA; PNEUMOCOCCAL VACCINES; PRIMARY PREVENTION;

EID: 81555230490     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-882     Document Type: Article

References (46)

1. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, Eisele T, Liu L, Mathers C, Child Health Epidemiology Reference Group of WHO and UNICEF, Lancet 2010 375 1969 87 10.1016/S0140-6736(10)60549-1 20466419
2. Advance Market Commitments for Vaccines Update: World's Poorest Children Among First to Receive New Life-Saving Pneumococcal Vaccines. Global Alliance for Vaccines and Immunization, 2010 http://www.gavialliance.org/library/news/ press-releases/2010/world-s-poorest-children-among-first-to-receive-new-life- saving-pneumococcal-vaccines/
3. Optimal sampling sites and methods for detection of pathogens possibly causing community-acquired lower respiratory tract infections. Loens K, Van HL, Malhotra-Kumar S, Goossens H, Ieven M, J Clin Microbiol 2009 47 21 31 10.1128/JCM.02037-08 19020070
4. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Black SB, Shinefield HR, Ling S, Hansen J, Fireman B, Spring D, Noyes J, Lewis E, Ray P, Lee J, Hackell J, Pediatr Infect Dis J 2002 21 810 5 10.1097/00006454-200209000-00005 12352800
5. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, N Engl J Med 2003 349 1341 8 10.1056/NEJMoa035060 14523142 (Pubitemid 37186212)
6. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, McAdam KP, Biney E, Saaka M, Onwuchekwa U, Yallop F, Pierce NF, Greenwood BM, Adegbola RA, Gambian Pneumococcal Vaccine Trial Group, Lancet 2005 365 1139 46 10.1016/S0140-6736(05) 71876-6 15794968 (Pubitemid 40417563)
7. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B, Lewis E, Ray P, Lee J, Pediatr Infect Dis J 2006 25 779 81 10.1097/01.inf.0000232706.35674.2f 16940833 (Pubitemid 44325778)
8. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Lucero MG, Nohynek H, Williams G, Tallo V, Simões EA, Lupisan S, Sanvictores D, Forsyth S, Puumalainen T, Ugpo J, Lechago M, de Campo M, Abucejo-Ladesma E, Sombrero L, Nissinen A, Soininen A, Ruutu P, Riley I, Mäkelä HP, Pediatr Infect Dis J 2009 28 455 62 10.1097/INF.0b013e31819637af 19483514
9. Global prevailing and emerging pediatric pneumococcal serotypes. McIntosh ED, Reinert RR, Expert Rev Vaccines 2011 10 109 29 10.1586/erv.10.145 21162625
10. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, Muenz LR, O'Brien KL, PLoS Med 2010 7 10
11. Invasive pneumococcal infections among hospitalized children in Bamako, Mali. Campbell JD, Kotloff KL, Sow SO, Tapia M, Keita MM, Keita T, Diallo S, Hormazabal JC, Murray P, Levine MM, Pediatr Infect Dis J 2004 23 642 9 10.1097/01.inf.0000130951.85974.79 15247603 (Pubitemid 38924889)
12. Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection. Bakaletz LO, Kennedy BJ, Novotny LA, Duquesne G, Cohen J, Lobet Y, Infect Immun 1999 67 2746 62 10338477 (Pubitemid 29244686)
13. Effects on the ciliated epithelium of protein D-producing and -nonproducing nontypeable Haemophilus influenzae in nasopharyngeal tissue cultures. Janson H, Carl n B, Cervin A, Forsgren A, Magnusdottir AB, Lindberg S, Runer T, J Infect Dis 1999 180 737 46 10.1086/314921 10438362 (Pubitemid 29411360)
14. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, Schuerman L, Lancet 2006 367 740 8 10.1016/S0140-6736(06)68304-9 16517274 (Pubitemid 43326292)
15. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Bermal N, Szenborn L, Chrobot A, Alberto E, Lommel P, Gatchalian S, Dieussaert I, Schuerman L, Pediatr Infect Dis J 2009 28 (Suppl 4):S89 S96
16. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, Borys D, Cleerbout J, Lommel P, Schuerman L, Pediatr Infect Dis J 2009 28 (Suppl 4):S109 S118
17. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Prymula R, Siegrist CA, Chlibek R, Zemlickova H, Vackova M, Smetana J, Lommel P, Kaliskova E, Borys D, Schuerman L, Lancet 2009 374 1339 50 10.1016/S0140-6736(09)61208-3 19837254
18. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène JP, Lommel P, Dieussaert I, Schuerman L, Pediatr Infect Dis J 2009 28 (Suppl 4):S66 S76
19. Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine. Silfverdal SA, Hogh B, Bergsaker MR, Skerlikova H, Lommel P, Borys D, Schuerman L, Pediatr Infect Dis J 2009 28 276 e282 10.1097/INF.0b013e3181b48ca3 20118683
20. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningitidis serogroup C conjugate vaccines. Wysocki J, Tejedor JC, Grunert D, Konior R, Garcia-Sicilia J, Knuf M, Bernard L, Dieussaert I, Schuerman L, Pediatr Infect Dis J 2009 28 (Suppl 4):S77 S88
21. Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children. Lagos RM, Munoz AE, Levine MM, Lepetic A, François N, Yarzabal JP, Schuerman L, Hum Vaccin 2011 7 511 22 10.4161/hv.7.5.14634 21441782
22. Immunization of preterm infants with 10-valent pneumococcal conjugate vaccine. Omenaca F, Merino JM, Tejedor JC, Constantopoulos A, Papaevangelou V, Kafetzis D, Tsirka A, Athanassiadou F, Anagnostakou M, François N, Borys D, Schuerman L, Pediatrics 2011 128 290 8 10.1542/peds.2010-1184 21727108
23. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Concepcion NF, Frasch CE, Clin Diagn Lab Immunol 2001 8 266 72 11238206 (Pubitemid 32217054)
24. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Henckaerts I, Goldblatt D, Ashton L, Poolman J, Clin Vaccine Immunol 2006 13 356 60 10.1128/CVI.13.3.356-360.2006 16522777
25. Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. Poolman JT, Frasch CE, Kayhty H, Lestrate P, Madhi SA, Henckaerts I, Clin Vaccine Immunol 2010 17 134 42 10.1128/CVI.00289-09 19889940
26. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, Keyserling HL, Carlone GM, Clin Diagn Lab Immunol 1997 4 415 22 9220157 (Pubitemid 27321773)
27. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J, Vaccine 2007 25 2518 27 10.1016/j.vaccine.2006.09.029 17034907 (Pubitemid 46366133)
28. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, Dieussaert I, Schuerman L, Pediatr Infect Dis J 2009 28 (Suppl 4):S97 S108
29. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Takala A, Käyhty H, Karma P, Kohberger R, Siber G, Mäkelä PH, Finnish Otitis Media Study Group, N Engl J Med 2001 344 403 9 10.1056/ NEJM200102083440602 11172176 (Pubitemid 32128672)
30. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, Grönholm M, Leinonen M, Hovi T, Eskola J, Käyhty H, Bohidar N, Sadoff JC, Mäkelä PH, Finnish Otitis Media Study Group, Clin Infect Dis 2003 37 1155 64 10.1086/378744 14557958 (Pubitemid 37372502)
31. Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses. Sigurdardottir ST, Davidsdottir K, Arason VA, Jonsdottir O, Laudat F, Gruber WC, Jonsdottir I, Vaccine 2008 26 4178 86 10.1016/j.vaccine.2008.05.072 18606481
32. Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine. Wuorimaa TK, Dagan R, Bailleux F, Haikala R, Ekström N, Eskola J, Yaich M, Käyhty H, Vaccine 2005 23 5328 32 10.1016/j.vaccine.2005.06.023 16118028 (Pubitemid 41579302)
33. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA, Pediatrics 2010 125 866 75 10.1542/peds.2009-1405 20435707
34. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A, Lancet 2006 368 1495 502 10.1016/S0140-6736(06)69637-2 17071283 (Pubitemid 44634693)
35. Opportunity and challenges for pneumococcal conjugate vaccines in low- and middle-income countries. Levine OS, Greenwood B, Pneumococcal vaccines: the impact of conjugate vaccines Washington, DC: ASM Press, Siber G, Klugman KP, Makela H, 2008 405 18
36. The potential indirect effect of conjugate pneumococcal vaccines. O'Brien KL, Dagan R, Vaccine 2003 21 1815 25 10.1016/S0264-410X(02)00807-1 12706665 (Pubitemid 36428771)
37. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. Dagan R, Givon-Lavi N, Greenberg D, Fritzell B, Siegrist CA, J Infect Dis 2010 201 1570 9 10.1086/652006 20384496
38. Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination. Vakevainen M, Soininen A, Lucero M, Nohynek H, Auranen K, Mäkelä PH, Williams G, Käyhty H, ARIVAC Consortium, J Pediatr 2010 157 778 83 10.1016/j.jpeds. 2010.04.071 20547399
39. Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization. Madhi SA, Violari A, Klugman KP, Lin G, McIntyre JA, von Gottberg A, Jean-Philippe P, Cotton MF, Adrian P, CIPRA 4 team, Vaccine 2011 29 6994 7001 10.1016/j.vaccine.2011.07.035 21787822
40. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Puumalainen T, Dagan R, Wuorimaa T, Zeta-Capeding R, Lucero M, Ollgren J, Käyhty H, Nohynek H, Pediatr Infect Dis J 2003 22 141 9 12586978 (Pubitemid 36228131)
41. A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth. Gatchalian S, Reyes M, Bermal N, Lefevre I, David MP, Han HH, Bock HL, Wolter J, Schuerman L, Hum Vaccin 2005 1 198 203 10.4161/hv.1.5.2163 17012860
42. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content. Hla KH, Thein SA, Aye A, Han HH, Bock HL, David MP, Schuerman L, Pediatr Infect Dis J 2006 25 706 12 10.1097/01.inf.0000223488.80814.df 16874170 (Pubitemid 44162128)
43. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life. Gatchalian S, Reyes M, Bermal N, Chandrasekaran V, Han HH, Bock HL, Lefevre I, Hum Vaccin 2008 4 60 6 10.4161/hv.4.1.5069 18376148 (Pubitemid 351785263)
44. Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial. Espinoza F, Tregnaghi M, Gentile A, Abarca K, Casellas J, Collard A, Lefevre I, Jacquet JM, BMC Infect Dis 2010 10 297 10.1186/1471-2334-10-297 20950456
45. The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule. Chatterjee S, Rego SJ, D'Souza F, Bhatia BD, Collard A, Datta SK, Jacquet JM, BMC Infect Dis 2010 10 298 10.1186/1471-2334-10-298 20950457
46. Synflorix. European Public Assessment Report. European Medicines Agency, 2011 http://www.ema.europa.eu/humandocs/Humans/EPAR/synflorix/synflorix.htm